cystic fibrosis

Patients living with cystic fibrosis (CF) are at increased risk for acquiring and developing severe respiratory infections. The most worrisome pathogen is Pseudomonas aeruginosa (PsA), which is treated with powerful antibiotics either via oral, intravenous, or inhaled antibiotics. While these treatments are known to work, there has yet to be a conclusive…

La Jolla Pharmaceutical Company has just announced it has entered two exclusive licensing agreements with the Indiana University Research and Technology Corporation (IURTC), and the IURTC and the University of Alabama at Birmingham (UAB). The agreements cover intellectual property rights for the company’s next-gen gentamicin derivatives, LJPC-30Sa and LJPC-30Sb, as antimicrobial agents…

Researchers at the University of Queensland in Australia recently reported that the mobility of cystic fibrosis (CF) patients between care centers increases the risk of transmission of the associated bacterial Pseudomonas aeruginosa infection. The study was published in the journal The Lancet Respiratory Medicine and is…

The first nanotechnology-enabled gene delivery system capable of efficiently penetrating the hard-to-breach mucus barrier shielding human airway and lung tissue may have been discovered with potential to one day develop an inhaled vehicle for delivery of targeted therapeutic genes that may be delivered directly to the lungs at levels sufficient…

In a special article published in the journal Mediators of Inflammation, a team of researchers led by Nades Palaniyar from the Lung Innate Immunity Research Laboratory at The Hospital for Sick Children Research Institute in Toronto, Canada reviewed the current research advances in the field of Cystic…

A study recently published in the journal mBio provided new insight into the conditions under which microorganisms that contribute to the development of cystic fibrosis (CF) survive and develop in children with the disease. The study was conducted by researchers at California Institute of Technology, the…

An increasing number of studies testing gene therapies are showing promise for treating a wide range of conditions, including cystic fibrosis. Normally in these studies, genes are injected into cells using a virus, however, scientists recently tested a new method of delivering DNA to the faulty CFTR gene in CF through what is called a cationic liposome, a fatty container…

Researchers at Aarhus University Hospital Skejby in Denmark recently reported new data regarding complications in outpatient parenteral antimicrobial therapy (OPAT) for effective treatment of pulmonary bacterial infections in cystic fibrosis (CF) patients. The study was published in the journal BMC Infectious Diseases and is entitled “…

PARI Respiratory Equipment, Inc., a leading, worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, cystic fibrosis, RSV, VAP, and HAP, recently reported on important news concerning its therapeutic products for US patients living with cystic fibrosis. Its proprietary Kitabis Pak (co-packaging…

A new study on the association between proteases and anti-proteases during Cystic fibrosis entitled “Changes of Proteases, Antiproteases, and Pathogens in Cystic Fibrosis Patients’ Upper and Lower Airways after IV-Antibiotic Therapy” was published this June in Mediators of Inflammation. Cystic fibrosis (CF) is the…